{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Steber CR"],"funding":["NCATS NIH HHS","NCI","NCI NIH HHS"],"pagination":["152-156"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8559790"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["111(1)"],"pubmed_abstract":["<h4>Purpose</h4>Long-term outcomes after external beam radiation therapy (EBRT) and radiofrequency ablation (RFA) for medically inoperable early-stage non-small cell lung cancer (NSCLC) are not well known.<h4>Methods and materials</h4>Patients with medically inoperable early-stage NSCLC were enrolled in a prospective single-arm, phase 2 study between June 2007 and October 2008 and were treated with RFA followed by EBRT. Radiation was delivered using hypofractionated radiation therapy (HFRT; 70.2 Gy in 26 fractions) or stereotactic body radiation therapy (54 Gy in 3 fractions).<h4>Results</h4>Twelve patients were evaluable; 10 patients were treated with HFRT. The cumulative incidence of local progression at 5 years was 16.7% (95% confidence interval [CI], 0-37.8). Median progression-free su"],"journal":["International journal of radiation oncology, biology, physics"],"pubmed_title":["Long-Term Outcomes From a Phase 2 Trial of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer."],"pmcid":["PMC8559790"],"funding_grant_id":["P30 CA012197","KL2 TR001421"],"pubmed_authors":["Hughes RT","Urbanic J","Clark H","Petty WJ","Blackstock AW","Steber CR","Farris MK"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Outcomes From a Phase 2 Trial of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer.","description":"<h4>Purpose</h4>Long-term outcomes after external beam radiation therapy (EBRT) and radiofrequency ablation (RFA) for medically inoperable early-stage non-small cell lung cancer (NSCLC) are not well known.<h4>Methods and materials</h4>Patients with medically inoperable early-stage NSCLC were enrolled in a prospective single-arm, phase 2 study between June 2007 and October 2008 and were treated with RFA followed by EBRT. Radiation was delivered using hypofractionated radiation therapy (HFRT; 70.2 Gy in 26 fractions) or stereotactic body radiation therapy (54 Gy in 3 fractions).<h4>Results</h4>Twelve patients were evaluable; 10 patients were treated with HFRT. The cumulative incidence of local progression at 5 years was 16.7% (95% confidence interval [CI], 0-37.8). Median progression-free su","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-18T18:43:19.382Z","creation":"2025-04-07T06:24:42.55Z"},"accession":"S-EPMC8559790","cross_references":{"pubmed":["33932531"],"doi":["10.1016/j.ijrobp.2021.04.020"]}}